Table 1.

Results of single-center and multicenter studies of HDM/SCT in AL amyloidosisa

ParameterNo. of PatientsMelphalan Dosage (mg/m2)TRM (%)CR (%)Organ Response (%)Survival
Single-center experience
    Reich et al., 2001 (40)4140 to 20050255050% at 1 yr
    Van Gameren et al., 2002 (41)11NANA06775% at 2 yr
    Blum et al., 2003 (42)12ND1527NANA
    Gertz et al., 2004 (47)171100 to 2001277bNANA
    Mollee et al., 2004 (44)20140 to 2003545NA56% at 3 yr
    Perz et al., 2004 (45)24100 to 2001352NA84% at 2 yr
    Skinner et al., 2004 (3)277100 to 20013404447% at 5 yr
    Chow et al., 2005 (46)15170 to 200 0672775% at 4 yr
Multicenter experience
    Moreau et al., 1998 (48)21140 to 20043258357% at 4 yr
    Vesole et al., 2006 (49)107140 to 200183656% at 3 yr
    Gertz et al., 2004 (43)2820014NA7562% at 3 yr
    Goodman et al., 2006 (50)92140 to 2002383bNA5.3 yr
  • a CR, complete hematologic response; HDM/SCT, high-dose melphalan and stem cell transplantation; NA, not applicable; ND, not determined; TRM, treatment-related mortality.

  • b Includes partial and complete hemotologic responses.